On Monday President Cyril Ramaphosa announced that South Africa will host the first World Health Organization-backed COVID-19 mRNA vaccine Technology Transfer Hub – an initiative designed to get the production of mRNA vaccines off the ground in Africa. Parties involved in the hub expect to hear as early as next week whether pharmaceutical companies with mRNA COVID-vaccines for COVID-19 on the market – Moderna and Pfizer/BioNTech – will share their know-how with the hub. Chris Bateman reports for Spotlight.
Biopharmaceuticals are therapeutic drugs, vaccines, and diagnostics in which the active ingredient is produced in a living substance such as eggs or tobacco plants. The living substance acts as a ‘miniature factory’ in which the active ingredient is grown and replicated. Catherine Tomlinson takes a deep dive into the fascinating research and other initiatives in South Africa aimed at spurring local production of these products – and asks why a Cape Town-based company opted to set up a manufacturing plant in Mauritius rather than at home.
South Africa has struggled to secure adequate stock of urgently needed COVID-19 vaccines. This has raised questions about the state of the country’s local vaccine manufacturing capacity and why, after almost two decades of government support, South Africa’s partially state-owned vaccine manufacturer Biovac is not better positioned to respond to the pandemic. Catherine Tomlinson investigates.
South Africa is set to produce its first vaccine in 25 years, but it won’t be a COVID-19 jab. Plans are however in place to “fill and finish” COVID-19 vaccines in South Africa. Laura Lopez Gonzalez has the details.